Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01339039 · ClinicalTrials.gov registry record · Phase 1
Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma
A Phase 1 study, sponsored by Patrick Y. Wen, MD.
- Terminated
- Registry status
- Phase 1
- Development phase
- 26
- Enrollment target
NCT01339039 is a Phase 1 study that was terminated before completion, run by Patrick Y. Wen, MD. The registered enrollment target is 26 participants.
The verdict
NCT01339039, a Phase 1 study, was terminated before completion, sponsored by Patrick Y. Wen, MD.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 26 participants
- Enrollment target
Study Summary
Plerixafor in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. Bevacizumab, also known as Avastin, is FDA approved for use in patients with recurrent glioblastoma and has been studied extensively in other types of solid tumors. Plerixafor, also known as Mozobil, is FDA approved for use in patients with non-Hodgkin's lymphoma and multiple myeloma and has been used in treatment for other cancers. Information from experiments in laboratories suggests that the combination of plerixafor and bevacizumab may help prevent the growth of gliomas. Part 1: The investigators are looking for the highest dose of plerixafor that can be given safely with bevacizumab (with a 21 days on/7 days off regimen of plerixafor). The investigators will also do blood tests to find out how the body uses and breaks down the drug combination. Part 2: The investigators are looking to see if plerixafor can get past the blood-brain barrier and into brain tumors. The investigators will also do blood tests to find out how the body uses and breaks down the drug combination. Part 3: The investigators are looking for for more information re: safety and tolerability of plerixafor in combination with bevacizumab (with a 28 days on/0 days off regimen of plerixafor). The investigators will also do blood tests to find out how the body uses and breaks down the drug combination.
Interventions
- DRUG Bevacizumab
- PROCEDURE Surgery
- DRUG Plerixafor
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2011-12 |
| Est. Completion | 2017-04-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01339039
The ClinicalTrials.gov registry entry for NCT01339039 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Patrick Y. Wen, MD, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Bevacizumab is the first listed.
NCT01339039 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01339039 about?
NCT01339039 is a clinical study titled "Plerixafor (AMD3100) and Bevacizumab for Recurrent High-Grade Glioma". Plerixafor in combination with bevacizumab is a drug combination that may stop cancer cells from growing abnormally. Bevacizumab, also known as Avastin, is FDA approved for use in patients with recurrent glioblastoma and has been studied extensively in other types of solid tumors. Plerixafor, also k...
What is the current status of trial NCT01339039?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 26 participants. The study started on 2011-12. Estimated completion is 2017-04-08.
What interventions are being tested in trial NCT01339039?
The interventions under investigation include: Bevacizumab (DRUG), Surgery (PROCEDURE), Plerixafor (DRUG).
Who is sponsoring clinical trial NCT01339039?
This trial is sponsored by Patrick Y. Wen, MD, which has 7 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.